|
May 8
|
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
|
|
Feb 6
|
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
|
|
Dec 21
|
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
|
|
Dec 5
|
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
|
|
Dec 4
|
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
|
|
Dec 4
|
Biotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial Data
|
|
Dec 4
|
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
|
|
Nov 27
|
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
|